Development and Validation of a Prevalence Model for Latent Autoimmune Diabetes in Adults (LADA) Among Patients First Diagnosed with Type 2 Diabetes Mellitus (T2DM)

15 September 2021: Clinical Research

Zhida Wang ^1ABCDEF* , Jie Zhang ^2ABCDEF* , Hui Xu ^3CDEF , Liming Chen ^1ADEFG* , Abigail Dove ^4ADEF

DOI: 10.12659/MSM.932725

Med Sci Monit 2021; 27:e932725

Table 2 Comparison of the clinical features between model development and validation groups.

Clinical features	Model development group (n=632)	Model validation group (n=298)	Z/t/χ2	P value
Age	57 (49, 61)	56 (47, 62)	−0.366	0.714
Ketosis	46 (7.3%)	17 (5.7%)	0.794	0.373
Abdominal type obesity	534 (84.5%)	249 (83.6%)	0.133	0.715
Smoking	336 (53.2%)	142 (47.7%)	2.464	0.116
Clinical testing
HbA1c (%)	7.8 (7, 8.9)	7.6 (6.8, 8.7)	−	0.009
FPG	8.43 (7.60, 9.68)	8.42 (7.44, 9.54)	−0.748	0.454
1hPG	17.07±2.57	16.71±2.73	1.966	0.050
2hPG	16.95 (14.85, 19.37)	17.25±3.64	−0.398	0.691
1hINS	47.48 (31.75, 71.39)	47.97 (32.70, 75.33)	−0.397	0.691
2hINS	55.70 (36.23, 88.94)	60.84 (41.22, 93.35)	−	0.049
FCP	2.41 (1.90, 3.06)	2.31 (1.85, 3.02)	−1.413	0.158
1hCP	5.08 (3.99, 6.30)	4.81 (3.78, 6.13)	−	0.029
2hCP	6.48 (5.21, 8.37)	6.38 (5.13, 7.99)	−1.073	0.283
Pancreatic β-cell function
PG-AUC	30.02 (26.83, 32.85)	29.31 (26.31, 32.91)	−1.375	0.169
1hPG-AUC	12.86 (11.63, 14.11)	12.53 (11.31, 14.17)	−	0.046
2hPG-AUC	17.04 (15.19, 18.81)	16.86 (14.86, 18.92)	−0.859	0.390
INS-AUC	83.37 (56.62, 127.50)	86.11 (60.65, 135.45)	−0.953	0.341
1hINS-AUC	31.70 (21.18, 47.51)	32.02 (21.49, 48.49)	−0.307	0.759
2hINS-AUC	51.55 (34.81, 78.55)	56.24 (38.05, 86.14)	−1.278	0.201
CP-AUC	9.67 (7.74, 11.93)	9.26 (7.45, 11.63)	−1.948	0.051
1hCP-AUC	3.79 (3.06, 4.65)	3.57 (2.81, 4.59)	−	0.036
2hCP-AUC	5.83 (4.65, 7.29)	5.63 (4.51, 6.98)	−1.684	0.092
HOMA2-β (%)	52.90 (41.23, 67.48)	50.35 (40.05, 67.70)	−0.487	0.626